S1PR1 and myeloid sarcoma: The currently used pharmacological treatments for MS include beta interferons; corticosteroids; i.v. immunoglobulins; dimethyl fumarate; glatiramer acetate; the dihydroorotate dehydrogenase inhibitor, teriflunomide; the purine analog, cladribine; the sphingosine-1-phosphate receptor modulators, fingolimod, ozanimod, and siponimod; the anti–α4-integrin antibody, natalizumab; the anti-CD20 antibodies, ocrelizumab, rituximab, and ofatumumab; and the anti-CD52 antibody, alemtuzumab (19, 20, 21).